TherapeuticsMD receives Nasdaq delisting notice for bid price non-compliance; CFO resigns

TherapeuticsMD, Inc.

Received Nasdaq delisting notice on March 15, 2022 for failing to maintain $1.00 minimum bid price within 180-day compliance period.
Company requested a hearing to appeal; trading stay pending Panel decision.
Intends to consider reverse stock split to regain compliance with minimum bid price requirement.
CFO James C. D'Arecca resigns effective April 1, 2022; Michael C. Donegan appointed Interim CFO.
Search for permanent CFO initiated.

item 3.01 item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

James C. D’Arecca

Chief Financial Officer

TXMD · TherapeuticsMD, Inc.

Effective: 2022-04-01
Successor: Michael C. Donegan
Filed: March 18, 2022, 7:59 PM ET

On March 14, 2022, Mr. James C. D’Arecca, the Chief Financial Officer and Principal Financial Officer of the Company, notified the Company of his decision to resign from such positions, effective as of April 1, 2022.

Appointed (interim)

Michael C. Donegan

Interim Chief Financial Officer

TXMD · TherapeuticsMD, Inc.

Effective: 2022-04-01
Filed: March 18, 2022, 7:59 PM ET

Mr. Michael C. Donegan, the Vice President – Finance and Chief Accounting Officer of the Company, will succeed Mr. D’Arecca as Interim Chief Financial Officer and Principal Financial and Accounting Officer as of the effective date of Mr. D’Arecca’s resignation.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

James C. D’Arecca resigned as Chief Financial Officer at TherapeuticsMD, Inc..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

On March 14, 2022, Mr. James C. D’Arecca, the Chief Financial Officer and Principal Financial Officer of the Company, notified the Company of his decision to resign from such positions, effective as of April 1, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael C. Donegan was appointed as Interim Chief Financial Officer at TherapeuticsMD, Inc..

Action: appointed
Role: Interim Chief Financial Officer

Exact text from the filing

Mr. Michael C. Donegan, the Vice President – Finance and Chief Accounting Officer of the Company, will succeed Mr. D’Arecca as Interim Chief Financial Officer and Principal Financial and Accounting Officer as of the effective date of Mr. D’Arecca’s resignation.

View on SEC.gov

TherapeuticsMD, Inc. filing history →

Source: SEC EDGAR

accession 0001564590-22-011090

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.